Label

{
  "application_numbers": [
    "NDA209637"
  ],
  "as_of": "2026-10-21T09:00:00Z",
  "brand_names": [
    "Ozempic"
  ],
  "caveat": "Prescribing information as the manufacturer or repackager filed it with FDA; the newest matching label is served. Not medical advice.",
  "drug": "ozempic",
  "effective_date": "2026-07-30",
  "generic_names": [
    "SEMAGLUTIDE"
  ],
  "label_count": 4,
  "manufacturer": "A-S Medication Solutions",
  "modified": true,
  "product_type": "human prescription drug",
  "route": [
    "SUBCUTANEOUS"
  ],
  "rxcui": [
    "2619152",
    "2619154"
  ],
  "section": "",
  "sections": {
    "adverse_reactions": {
      "chars": 18230,
      "text": "6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: • Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] • Acute Pancreatitis [see Warnings and Precautions ( 5.2) ] • Diabetic Retinopathy Complications [see Warnings and Precautions ( 5.3 )] • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions ( 5.5 )] • Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.6 )] • Severe Gastrointestinal Adverse Reactions [see Warnings and Precaution…",
      "truncated": true
    },
    "boxed_warning": {
      "chars": 1695,
      "text": "WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome …",
      "truncated": true
    },
    "contraindications": {
      "chars": 570,
      "text": "4 CONTRAINDICATIONS OZEMPIC is contraindicated in patients with: • A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . • A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.8 )] . • Personal or family history of MTC or in patients with MEN 2. ( 4 ) • Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC. ( 4 )",
      "truncated": false
    },
    "dosage_and_administration": {
      "chars": 2987,
      "text": "2 DOSAGE AND ADMINISTRATION • Administer once weekly at any time of day, with or without meals. ( 2.1 ) • Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. ( 2.2 ) • If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. ( 2.2 ) • If additional glycemic control is needed, increase the dosage to 2 mg once weekly after at least 4 weeks on the 1 mg dosage. ( 2.2 ) • To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg o…",
      "truncated": true
    },
    "drug_interactions": {
      "chars": 2279,
      "text": "7 DRUG INTERACTIONS Oral Medications : OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution. ( 7.2 ) 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving OZEMPIC in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. When initiating OZEMPIC, consider reducing the dose of concomitantly admini…",
      "truncated": true
    },
    "indications_and_usage": {
      "chars": 1037,
      "text": "1 INDICATIONS AND USAGE OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist ind…",
      "truncated": true
    },
    "warnings": {
      "chars": 13916,
      "text": "5 WARNINGS AND PRECAUTIONS • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC. Discontinue if pancreatitis is suspected. ( 5.2 ) • Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. ( 5.3 ) • Never share an OZEMPIC pen between patients , even if the needle is changed. ( 5.4 ) • Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secret…",
      "truncated": true
    }
  },
  "set_id": "42bdd912-2393-44c4-b7e0-47672ca28991",
  "source": {
    "citation": "Data provided by the U.S. Food and Drug Administration (https://open.fda.gov). Normalized by x402 Atlas; not the agency's verbatim record.",
    "name": "openFDA (U.S. Food and Drug Administration)",
    "url": "https://open.fda.gov"
  },
  "substances": [
    "SEMAGLUTIDE"
  ],
  "unii": [
    "53AXN4NNHX"
  ],
  "version": "1"
}

# bash or zsh: see the payment challenge. Nothing is charged.
curl -sS -g -i 'https://fda-drugs.use.x402atlas.com/label?drug=ozempic'

# x402 v2 sends the challenge base64-encoded in the PAYMENT-REQUIRED header (v1 sends it in the body).
# To read the header:
curl -sS -g -o /dev/null -D - 'https://fda-drugs.use.x402atlas.com/label?drug=ozempic' \
  | grep -i '^payment-required:' | cut -d' ' -f2 | tr -d '\r' | base64 --decode

// npm i @x402/fetch @x402/evm viem
import { wrapFetchWithPayment, x402Client } from "@x402/fetch";
import { registerExactEvmScheme } from "@x402/evm/exact/client";
import { privateKeyToAccount } from "viem/accounts";

// Pays at most $0.01 per call.
const client = new x402Client().setSpendControls({ maxAmountPerPayment: "$0.01" });
registerExactEvmScheme(client, { signer: privateKeyToAccount(process.env.EVM_PRIVATE_KEY) });
const pay = wrapFetchWithPayment(fetch, client);

// Not sure it's safe to pay? ToolVet checks it first for $0.005. Pay for that from a separate
// client: this one is capped at $0.01 per payment. GET https://toolvet.app/api/v1/check?url=https%3A%2F%2Ffda-drugs.use.x402atlas.com%2Flabel
const res = await pay("https://fda-drugs.use.x402atlas.com/label?drug=ozempic");
console.log(res.status, await res.text());

# pip install "x402[requests,evm]"
import os
from eth_account import Account
from x402 import x402ClientSync
from x402.http.clients import x402_requests
from x402.mechanisms.evm import EthAccountSigner
from x402.mechanisms.evm.exact.register import register_exact_evm_client

# Pays at most $0.01 per call.
client = x402ClientSync().set_spend_controls({"max_amount_per_payment": "$0.01"})
register_exact_evm_client(client, EthAccountSigner(Account.from_key(os.environ["EVM_PRIVATE_KEY"])))

with x402_requests(client) as session:
    res = session.get("https://fda-drugs.use.x402atlas.com/label?drug=ozempic")
    print(res.status_code, res.text)